Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?

Domenico Tamburrino; Giovanni Guarneri; Stefano Partelli; Stefano Crippa; Massimo Falconi; Gabriele Capurso

doi:https://doi.org/10.1016/j.dld.2021.04.027

doi.org/10.1016/j.dld.2021.04.027

Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?

,

,

..., Gabriele Capurso

49

Digestive and Liver Disease4.50

Volume: 53, Issue: 8, Pages: 1065 - 1067

Published: Aug 1, 2021

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Most patients with PDAC are diagnosed with advanced stage, and the mean 5-year survival is as low as 7% [ [1] Bray F. Ferlay J. Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68394–342 Crossref Scopus (38105) Google Scholar ]. Several...